The European Commission Approves Zogenix’s FINTEPLA® (Fenfluramine) Oral Solution for the Treatment of Seizures in Dravet Syndrome

Print Friendly, PDF & Email

RE: EPILEPSY – DRAVEY SYNDROME: EMERYVILLE, Calif., Dec. 21, 2020 (GLOBE NEWSWIRE) — Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, announced today that the European Commission (EC) has granted marketing authorization for FINTEPLA ® (fenfluramine) oral solution for the treatment of seizures associated with Dravet syndrome as an add-on therapy […]